Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Add as a preferred source on Google
NEW YORK, May 04, 2018 -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held May 8-9, 2018 at Reed Smith, LLP in New York. Dr. Simpson’s presentation details are as follows:
Panel Presentation:
- Session: Disruptive Injectables & Oncology
- Date and Time: Tuesday, May 8 at 1:45-2:45 p.m. EST
- Location: Track 2 – Room C/D
Corporate Presentation:
- Date and Time: Tuesday, May 8 at 3:25-3:45 p.m. EST
- Location: Room A/B
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) and plan to initiate a Registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
Contact:
Delcath Investor Relations
Email: [email protected]
